Clinical Trial

Blood Biomarkers for Alzheimer Disease and Neuro-injury to Estimate the Association With Cognitive/Functional Decline and Mortality in a Real-world Population of GERiatric Hospitalized Patients (BAD-GER)

Study acronym: BAD-GER
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated February 27, 2026 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
The BAD-GER study is a multicenter, prospective, three-arm observational study serving to validate a prognostic biomarker algorithm for mortality and hospital readmission; this algorithm will be developed through the retrospective analysis of Alzheimer's Disease and neurodegeneration biomarkers in an already available discovery cohort of 700 previously hospitalized geriatric patients.
Trial Details
NCT Number NCT07435467
Lead Sponsor Istituto Nazionale di Ricovero e Cura per Anziani
Collaborators: Ministry of Health, Italy, University of Salento, IRCCS Multimedica, Azienda Ospedaliera Universitaria Policlinico "G. Martino"
Conditions Alzheimer Disease, Old Age; Dementia
Enrollment 400 participants
Start Date 2025-04-09
Primary Completion 2026-06-30 (estimated)
Study Completion 2026-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-02-27